Psychedelic Drug Market Could Reach $14.9 Billion by 2035, Report Says
The global psychedelic drug market could grow from $4.13 billion in 2025 to $14.9 billion by 2035, according to a new SNS Insider report. The forecast reflects a broader shift in mental health care, where ketamine, psilocybin, MDMA, and other compounds are moving from fringe interest into clinical, regulatory, and investor conversations.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Takeaway | What It Means |
|---|---|
| Market growth is accelerating | SNS Insider projects the global psychedelic drug market will reach $14.9 billion by 2035. |
| Ketamine leads today | Ketamine accounts for the largest share of current revenue, due partly to its established medical use. |
| Psilocybin may grow fastest | The report points to ongoing clinical trials and rising interest in depression treatment. |
| The United States remains central | The U.S. market could rise from $1.63 billion in 2025 to $5.09 billion by 2035. |
| Mental health demand is driving interest | Depression, PTSD, anxiety, and substance use disorders remain major areas of unmet need. |
| Access is still uneven | Regulation, cost, provider training, and insurance coverage will shape real world growth. |
Do you work in the ketamine industry? Save thousands on overhead and other fees by joining the first GPO for ketamine clinics and practitioners. There’s no cost to join and zero obligations. Sign up here!
A Market Built Around Unmet Need
The report frames psychedelic medicine as a response to a familiar problem. Millions of patients still do not get enough relief from standard psychiatric treatments.
For HealingMaps readers, that context matters. Market forecasts can sound abstract. But behind the numbers are people with treatment resistant depression, severe anxiety, PTSD, and substance use disorders.
Existing medications help many patients. Yet they often take weeks to work. Others stop working over time or cause side effects that patients cannot tolerate.
That gap has created room for a different kind of treatment model. Psychedelic medicine often pairs a drug with structured clinical support. In ketamine care, that may include medical screening, monitored sessions, integration support, and follow up.
Why Ketamine Leads the Market
Ketamine currently holds the largest share of the psychedelic drug market, according to the report. That is not surprising.
Unlike many emerging psychedelic compounds, ketamine already has a long medical history as an anesthetic. Clinics also use it legally in mental health settings, often for depression that has not responded to other treatments.
This gives ketamine a practical advantage. Patients can access care now, depending on state rules, provider availability, and clinical fit.
Still, ketamine is not the only area attracting attention. The report identifies psilocybin as a faster growing segment, driven by clinical research and interest in depression care. MDMA, DMT, ibogaine, LSD, and other compounds also remain part of the broader market discussion.
Growth Will Depend on More Than Demand
The strongest market forecast does not guarantee broad access.
Psychedelic medicine still faces major hurdles. Regulators need stronger data. Clinicians need training. Clinics need clear standards. Patients need better information about safety, cost, and realistic outcomes.
Insurance coverage may become one of the biggest barriers. Many ketamine treatments remain out of pocket. Future psychedelic therapies may face similar challenges unless payers see convincing evidence of value.
For patients, the signal is clear. Psychedelic medicine is becoming a larger part of mental health care. But growth alone does not answer the most important question.
Can these treatments become safe, ethical, affordable, and clinically useful at scale? That will determine whether the market reaches its forecast, and whether patients benefit from it.
